
    
      This is a exploratory, single-arm, open-label,multicenter phase II trial. Our primary purpose
      is to compare that PFS of patients with pyrotinib plus trastuzumab and AI for HER2-positive
      and hormone receptor-positive MBC or locally advanced breast cancer (LABC).

      In treatment period, patients will be administrated pyrotinib plus trastuzumab and aromatase
      inhibitors, every 21 days for 1 cycle, until disease progression, toxicity intolerance,
      withdrawal of informed consent, patients judged must be terminated study termination.

      The imaging evaluation was performed according to the RECIST 1.1 criteria every 6 weeks.
    
  